Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationClear · blood-based contexts
Clear Blood
Molecular residual disease surveillance for blood-based and haematological contexts, so follow-up is as early and precise as possible.
Clear Blood
MRD surveillance for blood-based contexts
After curative-intent treatment, Clear Blood monitors for the molecular signals of returning disease in blood-based and haematological contexts, so follow-up can be as early and precise as possible.
It tracks disease-specific molecular markers over time from a simple blood draw, with each result read against your baseline and history.
How it works
- Step 1Baseline
Establish your molecular starting point after treatment.
- Step 2Scheduled monitoring
Planned blood draws on a subscription cadence.
- Step 3Interpretation
Each result is read in context by the engine.
- Step 4Clinician review
A changing signal triggers KPCIRC review and a plan.
Honest limits
MRD surveillance improves the chance of catching a return early, but no test detects every recurrence, and a negative result is reassuring rather than absolute. Clear Blood complements your scheduled clinical follow-up. It does not replace it.
Being clear about our limits
What we do and do not do
What we DO
- Watch for returning disease after curative-intent treatment
- Often flag recurrence earlier than routine imaging
- Trigger a KPCIRC clinician review on a changing signal
- Personalise how closely follow-up is done
What we DON’T do
- Diagnose recurrence on its own, findings are confirmed
- Detect every recurrence, since some tumours shed little ctDNA
- Replace your scheduled scans and specialist follow-up
- Guarantee that acting earlier will change the outcome
Plain-language glossary (5 terms)
| Term | What it means |
|---|---|
| MRD | Molecular residual disease, microscopic disease left after treatment. |
| ctDNA | Circulating tumour DNA, tumour fragments a blood test can read. |
| Tumour-informed | An MRD test built from your own tumour’s mutations, for higher sensitivity. |
| Recurrence | The cancer returning after a period of remission. |
| Lead time | How far ahead of a scan a blood test can flag returning disease. |
Important information and regulatory status
Clear Blood is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal